{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:35:06Z","timestamp":1785418506539,"version":"3.56.0"},"reference-count":65,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["SI868\/26-1"],"award-info":[{"award-number":["SI868\/26-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["KR2291\/15-1"],"award-info":[{"award-number":["KR2291\/15-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["SI868\/28-1"],"award-info":[{"award-number":["SI868\/28-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["SI868\/33-1"],"award-info":[{"award-number":["SI868\/33-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["KR2291\/12-2"],"award-info":[{"award-number":["KR2291\/12-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["KR2291\/14-1"],"award-info":[{"award-number":["KR2291\/14-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["KR2291\/16-1"],"award-info":[{"award-number":["KR2291\/16-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["KR2291\/17-1"],"award-info":[{"award-number":["KR2291\/17-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"award":["SI868\/26-1"],"award-info":[{"award-number":["SI868\/26-1"]}],"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"publisher"}]},{"award":["KR2291\/15-1"],"award-info":[{"award-number":["KR2291\/15-1"]}],"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"publisher"}]},{"award":["SI868\/28-1"],"award-info":[{"award-number":["SI868\/28-1"]}],"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"publisher"}]},{"award":["SI868\/33-1"],"award-info":[{"award-number":["SI868\/33-1"]}],"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"publisher"}]},{"award":["KR2291\/12-2"],"award-info":[{"award-number":["KR2291\/12-2"]}],"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"publisher"}]},{"award":["KR2291\/14-1"],"award-info":[{"award-number":["KR2291\/14-1"]}],"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"publisher"}]},{"award":["KR2291\/16-1"],"award-info":[{"award-number":["KR2291\/16-1"]}],"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"publisher"}]},{"award":["KR2291\/17-1"],"award-info":[{"award-number":["KR2291\/17-1"]}],"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Brigitte und Dr. Konstanze Wegener-Stiftung","award":["110"],"award-info":[{"award-number":["110"]}]},{"name":"Walter Schulz Stiftung"},{"DOI":"10.13039\/501100005677","name":"Deutsche Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","award":["DJCLS 09 R\/2024"],"award-info":[{"award-number":["DJCLS 09 R\/2024"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"award":["DJCLS 09 R\/2024"],"award-info":[{"award-number":["DJCLS 09 R\/2024"]}],"id":[{"id":"https:\/\/ror.org\/00826gz80","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004426","name":"Dr. Werner Jackst\u00e4dt-Stiftung","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004426","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/031gcry19","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021372","name":"H.W & J. Hector Stiftung","doi-asserted-by":"crossref","award":["M 2419"],"award-info":[{"award-number":["M 2419"]}],"id":[{"id":"10.13039\/501100021372","id-type":"DOI","asserted-by":"crossref"}]},{"award":["M 2419"],"award-info":[{"award-number":["M 2419"]}],"id":[{"id":"https:\/\/ror.org\/0427ycx88","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Acute myeloid leukemia (AML) is a hematological malignancy frequently driven by mutations in the FLT3 gene, particularly internal tandem duplications (FLT3-ITD), which contribute to aberrant cell proliferation and resistance to tyrosine kinase inhibitors (FLT3i). The limitations of current FLT3i therapies, including drug resistance, off-target effects, and poor selectivity, necessitate the development of novel therapeutic strategies. Proteolysis-targeting chimeras (PROTACs) represent a promising approach to achieving degradation of oncogenic proteins. Methods: We developed FLT3-targeting PROTACs based on the previously described compound MA49, with a focus on linker modifications to improve degradation efficiency and pharmacokinetic properties. Results: Among these, compounds MA190 and MA191, containing rigid cyclohexyl-piperidine\/piperazine linkers, demonstrate superior degradation of FLT3-ITD in MV4-11 AML cells at nanomolar concentrations, achieving &gt;95% reduction in FLT3-ITD levels, outperforming MA49. In addition to improved kinase selectivity, good solubility, and plasma stability, MA190 and MA191 also exhibit excellent metabolic stability, whereas the predecessor PROTAC MA49 was unstable in microsomal assays. In cellular assays, MA190 and MA191 induce potent apoptosis in FLT3-ITD+ AML cells but have minimal effects on cells with wild-type FLT3. Proteomics reveal that MA191 also degrades MAPK14 (p38\u03b1), a kinase upregulated in leukemia, in addition to FLT3. Conclusions: Dual targeting of FLT3-ITD and MAPK14 enhances proapoptotic signaling without any cytotoxic effect on normal human HEK293 cells. The co-inhibition using MA191 or a combination of doramapimod (a MAPK14 inhibitor) with a non-degrading FLT3 inhibitor result in greater caspase-3 activation than either treatment alone. This synergistic effect can be a therapeutic advantage, as several oncogenic drivers are switched off simultaneously by MA191.<\/jats:p>","DOI":"10.3390\/ph19050756","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T12:14:52Z","timestamp":1779452092000},"page":"756","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual FLT3\/MAPK14 Proteolysis-Targeting Chimera (PROTAC) Induces Potent Acute Myeloid Leukemia Cell Death"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6559-2527","authenticated-orcid":false,"given":"Mohamed","family":"Abdelsalam","sequence":"first","affiliation":[{"name":"Institute of Pharmacy, Martin-Luther University of Halle-Wittenberg, 06120 Halle, Germany"},{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melisa","family":"Halilovic","sequence":"additional","affiliation":[{"name":"Institute of Toxicology, University Medical Center, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6474-113X","authenticated-orcid":false,"given":"Ramy","family":"Ashry","sequence":"additional","affiliation":[{"name":"Institute of Toxicology, University Medical Center, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6442-1694","authenticated-orcid":false,"given":"Husam","family":"Nassar","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy, Martin-Luther University of Halle-Wittenberg, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5261-0984","authenticated-orcid":false,"given":"Frank","family":"Erdmann","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy, Martin-Luther University of Halle-Wittenberg, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3876-2695","authenticated-orcid":false,"given":"Matthias","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy, Martin-Luther University of Halle-Wittenberg, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3973-045X","authenticated-orcid":false,"given":"Oliver H.","family":"Kr\u00e4mer","sequence":"additional","affiliation":[{"name":"Institute of Toxicology, University Medical Center, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5985-9261","authenticated-orcid":false,"given":"Wolfgang","family":"Sippl","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy, Martin-Luther University of Halle-Wittenberg, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1756-8722-4-13","article-title":"Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: Biology and therapeutic implications","volume":"4","author":"Takahashi","year":"2011","journal-title":"J. Hematol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1046\/j.1365-2141.2003.04500.x","article-title":"Flt3 mutations and leukaemia","volume":"122","author":"Kottaridis","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrc1169","article-title":"The role of FLT3 in haematopoietic malignancies","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1021\/acs.jmedchem.0c01851","article-title":"FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"M\u00fcller, J.P., and Schmidt-Arras, D. (2020). Novel Approaches to Target Mutant FLT3 Leukaemia. Cancers, 12.","DOI":"10.3390\/cancers12102806"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"104139","DOI":"10.1016\/j.critrevonc.2023.104139","article-title":"FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review","volume":"191","author":"Dokla","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/leu.2015.165","article-title":"FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors","volume":"29","author":"Smith","year":"2015","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Ge, S.-S., Liu, S.-B., and Xue, S.-L. (2022). Developments and challenges of FLT3 inhibitors in acute myeloid leukemia. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.996438"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Eguchi, M., Minami, Y., Kuzume, A., and Chi, S. (2020). Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Biomedicines, 8.","DOI":"10.3390\/biomedicines8080245"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5306\/wjco.v9.i5.90","article-title":"Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies","volume":"9","author":"Zhou","year":"2018","journal-title":"World J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s12185-013-1334-8","article-title":"FLT3 inhibitors for acute myeloid leukemia: A review of their efficacy and mechanisms of resistance","volume":"97","author":"Grunwald","year":"2013","journal-title":"Int. J. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1182\/blood-2008-09-177030","article-title":"A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response","volume":"113","author":"Pratz","year":"2009","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"118212","DOI":"10.1016\/j.ejmech.2025.118212","article-title":"Design, synthesis and biological evaluation of 8-phenylquinazolin-2-amine derivatives as FLT3 covalent inhibitors targeting cysteine 828 in the ATP pocket","volume":"301","author":"Wei","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"114292","DOI":"10.1016\/j.ejmech.2022.114292","article-title":"Synthesis of 2H-Imidazo[2\u2032,1\u2032:2,3] [1,3]thiazolo[4,5-e]isoindol-8-yl-phenylureas with promising therapeutic features for the treatment of acute myeloid leukemia (AML) with FLT3\/ITD mutations","volume":"235","author":"Cilibrasi","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"115860","DOI":"10.1016\/j.ejmech.2023.115860","article-title":"Discovery of benzimidazole-indazole derivatives as potent FLT3-tyrosine kinase domain mutant kinase inhibitors for acute myeloid leukemia","volume":"262","author":"Ko","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s43556-022-00112-0","article-title":"An overview of PROTACs: A promising drug discovery paradigm","volume":"3","author":"Liu","year":"2022","journal-title":"Mol. Biomed."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-020-00924-z","article-title":"Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies","volume":"13","author":"He","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Kim, H., Park, J., and Kim, J.-M. (2022). Targeted Protein Degradation to Overcome Resistance in Cancer Therapies: PROTAC and N-Degron Pathway. Biomedicines, 10.","DOI":"10.3390\/biomedicines10092100"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"16428","DOI":"10.1021\/jacs.8b10320","article-title":"Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion","volume":"140","author":"Burslem","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"105508","DOI":"10.1016\/j.bioorg.2021.105508","article-title":"Degrading FLT3-ITD protein by proteolysis targeting chimera (PROTAC)","volume":"119","author":"Chen","year":"2022","journal-title":"Bioorg. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"16497","DOI":"10.1021\/acs.jmedchem.1c00996","article-title":"Proteolysis-Targeting Chimera (PROTAC) Modification of Dovitinib Enhances the Antiproliferative Effect against FLT3-ITD-Positive Acute Myeloid Leukemia Cells","volume":"64","author":"Cao","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"129041","DOI":"10.1016\/j.bmcl.2022.129041","article-title":"Sunitinib-based Proteolysis Targeting Chimeras (PROTACs) reduced the protein levels of FLT-3 and c-KIT in leukemia cell lines","volume":"78","author":"Zhai","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7197","DOI":"10.1021\/acs.jmedchem.4c00051","article-title":"Discovery of a Novel Orally Bioavailable FLT3-PROTAC Degrader for Efficient Treatment of Acute Myeloid Leukemia and Overcoming Resistance of FLT3 Inhibitors","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"115974","DOI":"10.1016\/j.ejmech.2023.115974","article-title":"Discovery of LWY713 as a potent and selective FLT3 PROTAC degrader with in vivo activity against acute myeloid leukemia","volume":"264","author":"Liu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"216933","DOI":"10.1016\/j.canlet.2024.216933","article-title":"FLT3-selective PROTAC: Enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia","volume":"592","author":"Tan","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1021\/acsmedchemlett.2c00402","article-title":"Development of Gilteritinib-Based Chimeric Small Molecules that Potently Induce Degradation of FLT3-ITD Protein","volume":"13","author":"Ohoka","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1038\/s41375-024-02405-5","article-title":"Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins","volume":"38","author":"Halilovic","year":"2024","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: A multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1016\/j.apsb.2024.04.007","article-title":"Characteristic roadmap of linker governs the rational design of PROTACs","volume":"14","author":"Dong","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","article-title":"Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead","volume":"25","author":"Bondeson","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/med.21877","article-title":"Strategies for designing proteolysis targeting chimaeras (PROTACs)","volume":"42","author":"He","year":"2022","journal-title":"Med. Res. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e3126","DOI":"10.1002\/ardp.202500102","article-title":"Ternary Complex Modeling, Induced Fit Docking and Molecular Dynamics Simulations as a Successful Approach for the Design of VHL-Mediated PROTACs Targeting the Kinase FLT3","volume":"358","author":"Nassar","year":"2025","journal-title":"Arch. Pharm."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acsmedchemlett.9b00025","article-title":"Identification of New Small-Molecule Inducers of Estrogen-related Receptor \u03b1 (ERR\u03b1) Degradation","volume":"10","author":"Peng","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/acs.jmedchem.8b01572","article-title":"Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)","volume":"62","author":"Hu","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"14237","DOI":"10.1021\/acs.jmedchem.2c01454","article-title":"Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS\/BRAF Mutant Cells","volume":"65","author":"Yu","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"14230","DOI":"10.1021\/acs.jmedchem.1c00517","article-title":"Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition","volume":"64","author":"Pal","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_40","unstructured":"Sasmal, S., Samajdar, S., Mukherjee, S., and Abbineni, C. (2025). Pyridazine Derivatives as SMARCA2\/4 Degraders. (US20210253564A1), Aurigene Discovery Technologies Ltd."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule\u2013kinase interaction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.chembiol.2017.10.010","article-title":"Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement","volume":"25","author":"Vasta","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"100822","DOI":"10.1016\/j.xpro.2021.100822","article-title":"Single tracer-based protocol for broad-spectrum kinase profiling in live cells with NanoBRET","volume":"2","author":"Robers","year":"2021","journal-title":"STAR Protoc."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1158\/1535-7163.MCT-12-0129","article-title":"Breakdown of the FLT3-ITD\/STAT5 Axis and Synergistic Apoptosis Induction by the Histone Deacetylase Inhibitor Panobinostat and FLT3-Specific Inhibitors","volume":"11","author":"Pietschmann","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.chembiol.2021.10.011","article-title":"Identification of a highly efficient dual type I\/II FMS-like tyrosine kinase inhibitor that disrupts the growth of leukemic cells","volume":"29","author":"Beyer","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"123401","DOI":"10.1016\/j.lfs.2025.123401","article-title":"Pharmacologically induced proteolysis of histone deacetylase-6 attenuates influenza virus replication despite limited anti-tumor effects","volume":"363","author":"Jungwirth","year":"2025","journal-title":"Life Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.1039\/D2CS00387B","article-title":"Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders","volume":"51","author":"Diehl","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41375-022-01798-5","article-title":"Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling","volume":"37","author":"Anderson","year":"2023","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1021\/ac9912247","article-title":"A High-Throughput Screening Method for the Determination of Aqueous Drug Solubility Using Laser Nephelometry in Microtiter Plates","volume":"72","author":"Bevan","year":"2000","journal-title":"Anal. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/1520-6017(200104)90:4<521::AID-JPS1009>3.0.CO;2-B","article-title":"Comparison of chromatographic and spectroscopic methods used to rank compounds for aqueous solubility","volume":"90","author":"Pan","year":"2001","journal-title":"J. Pharm. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Halilovic, M., Abdelsalam, M., Mieland, A.O., Neuroth, S., Ashry, R., Zabkiewicz, J., Lazenby, M., Alvares, C., Schmidt, M., and Brenner, W. (2025). Rapid proteasomal degradation of mutant feline McDonough sarcoma-like tyrosine kinase-3 overcomes tyrosine kinase inhibitor resistance of acute myeloid leukemia cells. bioRxiv.","DOI":"10.1101\/2025.06.20.660791"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1021\/acs.jmedchem.0c01846","article-title":"Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy","volume":"64","author":"Dragovich","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e202200615","DOI":"10.1002\/cmdc.202200615","article-title":"Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design","volume":"18","author":"Krieger","year":"2023","journal-title":"ChemMedChem"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"110570","DOI":"10.1016\/j.compbiomed.2025.110570","article-title":"HADDOCK-Guided modeling and molecular simulations of cereblon-based ternary complexes: Development of novel PROTACs for Ataxia telangiectasia and RAD3-Related (ATR) kinase","volume":"194","author":"Sarnow","year":"2025","journal-title":"Comput. Biol. Med."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Wang, K., Kuerbana, K., Wan, Q., Yu, Z., Ye, L., and Chen, Y. (2020). Introduction of Mercaptoethyl at Sorafenib Pyridine-2-Amide Motif as a Potentially Effective Chain to Further get Sorafenib-PEG-DGL. Molecules, 25.","DOI":"10.3390\/molecules25030573"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","article-title":"OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical Space","volume":"17","author":"Lu","year":"2021","journal-title":"J. Chem. Theory Comput."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/jcc.20933","article-title":"The generalized Born\/volume integral implicit solvent model: Estimation of the free energy of hydration using London dispersion instead of atomic surface area","volume":"29","author":"Labute","year":"2008","journal-title":"J. Comput. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1021\/acs.jmedchem.7b00675","article-title":"Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel\u2013Lindau (VHL) E3 Ubiquitin Ligase: Structure\u2013Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298)","volume":"61","author":"Soares","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1016\/j.bmcl.2010.07.134","article-title":"Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region","volume":"20","author":"Ahn","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e38430","DOI":"10.7554\/eLife.38430","article-title":"Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome","volume":"7","author":"Donovan","year":"2018","journal-title":"eLife"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"100279","DOI":"10.1016\/j.mcpro.2022.100279","article-title":"Rapid and In-Depth Coverage of the (Phospho-)Proteome With Deep Libraries and Optimal Window Design for dia-PASEF","volume":"21","author":"Skowronek","year":"2022","journal-title":"Mol. Cell. Proteom."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41592-019-0638-x","article-title":"DIA-NN: Neural networks and interference correction enable deep proteome coverage in high throughput","volume":"17","author":"Demichev","year":"2020","journal-title":"Nat. Methods"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Baek, K., Metivier, R.J., Burman, S.S.R., Bushman, J.W., Yoon, H., Lumpkin, R.J., Abeja, D.M., Lakshminarayan, M., Yue, H., and Ojeda, S. (2024). Unveiling the hidden interactome of CRBN molecular glues with chemoproteomics. bioRxiv.","DOI":"10.1101\/2024.09.11.612438"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/5\/756\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T04:16:55Z","timestamp":1779509815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/5\/756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":65,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["ph19050756"],"URL":"https:\/\/doi.org\/10.3390\/ph19050756","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]}}}